Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Programs and Projects

Prostate Cancer Clinical Trials - Roswell Park Cancer Institute

Agent: L-Selenomethionine
Contact: James Marshall, MD
DCP Program Director: Howard Parnes, MD

The purpose of this study is evaluate the potential of selenium as a chemopreventive agent for prostate cancer. Men with a diagnosis of prostate cancer who are considering surgical removal of the prostate gland (prostatectomy) or seed implants (brachytherapy) may be eligible to participate in this study. Those taking part in the study will receive selenium for several weeks immediately before prostate surgery or radiation therapy. The study is now open to accrual.

[This is a phase 2 randomized double-blind placebo controlled trial of three doses of l-Selenomethionine administered for 8 to 9 weeks in the period prior to prostatectomy or brachytherapy in men with localized prostate cancer. The primary endpoint is to evaluate the down-regulation of the androgen receptor in benign tissue by short-term selenium supplementation.]